Biotron (ASX:BIT) has provided an update on the BIT225-012 Phase 2 clinical trial of its lead antiviral drug BIT225 for treating COVID-19.
Latest Video
New Stories
-
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 - - Latest News -
Medicines Australia responds to questions on the HTA Review
September 16, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number two of five
September 16, 2024 - - Latest News -
Australian company Kazia executes licensing agreement with QIMR Berghofer
September 16, 2024 - - Latest News -
A statement with intent that limits expectations and frames reform as a one-sided trade-off
September 16, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number one of five
September 16, 2024 - - Latest News -
Pharmac announces plan to deploy more of its recent funding boost
September 16, 2024 - - Latest News